Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MERCK & CO., INC.

(MRK)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck Says Keytruda Liver Cancer Study Meets Objective

09/27/2021 | 05:56am EDT

By Michael Dabaie

Merck & Co. Inc. said the Phase 3 Keynote-394 trial investigating Keytruda in Asian patients with advanced hepatocellular carcinoma, a form of liver cancer, met its primary objective of overall survival.

Hepatocellular carcinoma is the most common form of primary liver cancer, which is the sixth most frequently diagnosed cancer worldwide. Keynote-394 looked at patients previously treated with sorafenib.

The study found that treatment with Keytruda plus best supportive care resulted in a statistically significant improvement in overall survival compared with placebo plus best supportive care. The study also met its key secondary endpoints of progression-free survival and objective response rate, with statistically significant improvements for Keytruda compared with placebo.

"Frequently diagnosed at an advanced stage, hepatocellular carcinoma has one of the highest mortality rates of solid cancers. Despite recent progress, there remains an unmet need for anti-PD-1 monotherapy after sorafenib, where Keytruda is an established treatment option for patients," said Dr. Scot Ebbinghaus, vice president of clinical research for Merck Research Laboratories.

Keytruda was granted accelerated approval in November 2018 for the treatment of patients with HCC who have been previously treated with sorafenib, based on ORR and durability of response data from the Keynote-224 study. A subsequent study, Keynote-240, didn't meet its dual primary endpoints of OS and PFS.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

09-27-21 0756ET

All news about MERCK & CO., INC.
10/15MERCK : And Co. Gets European Medicines Agency's Positive Opinions on Pneumonia Vaccine, C..
MT
10/15MERCK : Receives Positive Opinions From European Medicines Agency on Pneumonia Vaccine, Ca..
MT
10/15Merck, Eisai Get CHMP Backing for Lenvima-Keytruda Combo in Two Cancers
DJ
10/15MERCK : and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LEN..
BU
10/15MERCK : Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conj..
BU
10/15Merck Gets CHMP Positive Opinion for Vaxneuvance Vaccine
DJ
10/15MERCK : US FDA To Review Merck & Co.'s COVID-19 Antiviral Drug For Approval In Late Novemb..
MT
10/14MERCK : FDA to Review Merck's Emergency Use Authorization Request For Molnupiravir COVID-1..
MT
10/14MERCK : Nov 30th FDA Advisory Committee meeting to Discuss Merck & Ridgeback's COVID-19 An..
MT
10/14MERCK : Acceleron Pharma Shareholder Says Merck & Co.'s Offer Significantly Undervalues Co..
MT
More news
Analyst Recommendations on MERCK & CO., INC.
More recommendations
Financials (USD)
Sales 2021 48 042 M - -
Net income 2021 13 209 M - -
Net Debt 2021 17 557 M - -
P/E ratio 2021 16,3x
Yield 2021 3,36%
Capitalization 195 B 195 B -
EV / Sales 2021 4,43x
EV / Sales 2022 3,92x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | MarketScreener
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 77,15 $
Average target price 95,16 $
Spread / Average Target 23,3%
EPS Revisions
Managers and Directors
Robert M. Davis President, Chief Executive Officer & Director
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Kenneth C. Frazier Executive Chairman
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
MERCK & CO., INC.-4.24%198 283
JOHNSON & JOHNSON1.74%424 619
ROCHE HOLDING AG16.59%339 442
NOVO NORDISK A/S54.22%234 792
PFIZER, INC.12.71%232 621
ELI LILLY AND COMPANY41.54%215 657